Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean Infants

Inclusion Criteria: * Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study. * A male or female between, and including, 6 to 12 weeks of age at the time of the first dose of the vaccination. * Written informed consent obtained from the parents or guardians of the subject. * Healthy subjects as established by medical history and clinical examination before entering into the study. * Born after a normal gestation period of between 37 and 41 weeks + 6 days inclusive. * Subjects for whom the vaccination history is available from vaccination diary cards or medical charts. Exclusion Criteria: * Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the dose of study vaccine, or planned use during the study period. * Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth. * Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine with the exception of the routine infant vaccines. * Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract or other serious medical condition as determined by the investigator. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * Acute disease at the time of enrolment. * Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period. * Gastroenteritis (GE) within 7 days preceding the study vaccine administration. * Previous confirmed occurrence of RV GE. * Previous vaccination with rotavirus vaccine or planned use during the study period.